Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1629
This examiner grants 57% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18560113 | SELECTIVE, PARTIAL, AND ARRESTIN-BIASED 5-HT2A AGONISTS WITH UTILITY IN VARIOUS DISORDERS | Non-Final OA | The Regents of the University of California |
| 18516552 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | Non-Final OA | Genentech, Inc. |
| 18289409 | CONJUGATED LINOLEIC ACID SUPPLEMENTATION FOR DISEASE TREATMENT | Non-Final OA | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. |
| 18266179 | TREATMENT OF DISORDERS ASSOCIATED WITH LOW BH4 BIOAVAILABILITY | Non-Final OA | OXFORD UNIVERSITY INNOVATION LIMITED |
| 18446296 | Bi-functional Molecules To Degrade Circulating Proteins | Non-Final OA | YALE UNIVERSITY |
| 17756212 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ISCHEMIA-REPERFUSION INJURY AND/OR LUNG INJURY | Non-Final OA | YALE UNIVERSITY |
| 18039897 | METHOD OF TREATING POLYAMINE IMBALANCE-RELATED DISORDERS | Non-Final OA | UNIVERSITY OF MIAMI |
| 17744162 | USE OF SILDENAFIL AND ROCK INHIBITORS FOR TREATING STROKE OR SEQUELAE FOLLOWING STROKE | Non-Final OA | SOONCHUNHYANG UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION |
| 17412070 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | Final Rejection | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED |
| 18560280 | ETHACRYNIC ACID DERIVATIVES AS INHIBITORS OF MPRO PROTEASE AND SARS-COV-2 REPLICATION | Non-Final OA | UNIVERSITE EUROMEDITERRANEENNE DE FES |
| 17881302 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | Non-Final OA | Pharmacyclics LLC |
| 17560549 | USE OF ARIMOCLOMOL IN THE TREATMENT OF NIEMANN PICK DISEASE | Final Rejection | Zevra Denmark A/S |
| 18271991 | APPLICATION OF CILOSTAZOL-CONTAINING COMPOSITION IN PREPARING DRUG FOR TREATING CEREBROVASCULAR DISEASE | Non-Final OA | NEURODAWN PHARMACEUTICAL CO., LTD. |
| 17831843 | THERAPEUTIC DRUG FOR DISEASES RELATED TO ENDOPLASMIC RETICULUM CELL DEATH IN CORNEAL ENDOTHELIUM | Final Rejection | Senju Pharmaceutical Co., Ltd. |
| 17516313 | Hematocrit Modulation Through Needle Assisted Jet Injection of Testosterone | Non-Final OA | Antares Pharma, Inc. |
| 18317195 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | Non-Final OA | FibroGen, Inc. |
| 17739910 | Methods for Treating Visceral Fat Conditions | Final Rejection | Nalpropion Pharmaceuticals LLC |
| 18108320 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | Non-Final OA | AMO Pharma Ltd. |
| 18005269 | METHODS OF TREATING PROTEINOPATHIES | Non-Final OA | Woolsey Pharmaceuticals, Inc. |
| 17967255 | TREPROSTINIL ADMINISTRATION BY INHALATION | Non-Final OA | United Therapeutics Corporation |
| 17786154 | TREATING HEART DISEASE IN MUSCULAR DYSTROPHY PATIENTS | Final Rejection | Children`s Medical Center Corporation |
| 17749549 | METHODS AND COMPOSITIONS FOR CORRECTION OF AUTONOMIC DYSFUNCTIONS | Final Rejection | GENETIC DISEASE INVESTIGATORS, LLC |
| 17588273 | Treatment of cholangiopathies | Final Rejection | CymaBay Therapeutics, Inc. |
| 17337046 | PROGNOSTIC TUMOR BIOMARKERS | Final Rejection | M2Gen, Corp. |
| 16773094 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING METASTATIC TUMORS | Final Rejection | IMMUNE PHARMACEUTICALS, INC. |
| 16099035 | NANO-SYSTEMS FOR THERAPY AND/OR DIAGNOSIS AND/OR THERAPY MONITORING AND/OR THERANOSTICS OF DISEASE | Non-Final OA | UNIVERSITY OF EASTERN FINLAND |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy